Condition: Spinal and Bulbar Muscular Atrophy · Sponsor: Masahisa Katsuno
The purpose of this clinical trial is to evaluate the efficacy and safety of mexiletine hydrochloride in patients with spinal and bulbar muscular atrophy. The main questions it aims to answer are: Does mexiletine hydrochloride improve the ALSFRS-R score in spinal and bulbar muscular atrophy patients? Participants will: Take mexiletine hydrochloride or a placebo every day for 3 months Visit the hospital once every 4 weeks for evaluations.
This description comes directly from the study's public registry record.
Masahisa Katsuno, PhD, MD · +81527442389 · katsuno.masahisa.i1@f.mail.nagoya-u.ac.jp
Shinobu Shimizu, PhD · +81527442942 · shimizu.shinobu.w3@f.mail.nagoya-u.ac.jp
Always discuss trial participation with your own doctor first.
| Tokyo University Hospital | Bunkyō City, Japan | Recruiting |
| Chiba University Hospital | Chiba, Japan | Recruiting |
| Hokkaido University Hospital | Sapporo, Japan | Recruiting |
| Jichi Medical University Hospital | Shimotsuke, Japan | Recruiting |
| Osaka University Hospital | Suita, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06862596